Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

GU Cancers 2021 | Opaganib for mCRPC after abiraterone or enzalutamide

Omer Kucuk, MD, Winship Cancer Institute of Emory University, Atlanta, GA, gives an update on a Phase II trial (NCT04207255) evaluating the first-in-class sphingosine kinase-2 (SK2) selective inhibitor, opaganib, in patients with metastatic castration-resistant prostate cancer (mCRPC) progressing on abiraterone or enzalutamide. SK2 catalyzes formation of sphingosine 1-phosphate, which promotes cancer growth. The safety lead-in cohorts (1a and 1b) have now been completed. Enrolment is underway for cohort 2, trialling abiraterone plus opaganib, and cohort 3, trialling enzalutamide plus opaganib. A total of 60 patients will be enrolled. The primary endpoint of the study is stable disease or better after four cycles. This interview took place during the 2021 Genitourinary Cancers Symposium.

Choose your cookie settings

VJOncology uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.